Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Targeted Therapy Directed by Genetic Testing in Treating Patients with Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.

Disease Sites: Not Available

Phase: II

Investigator: Choe, Jennifer

NCTID: NCT05564377

Protocol No: VICC-NTMDT23238

Learn More

Identifying Best Approach in Improving Quality of Life and Survival after a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients with Blood Diseases

Hematologic

This phase II/III trial studies the best approach in improving quality of life and survival after a donor stem cell transplant in older, weak, or frail patients with blood diseases. Patients who have undergone a transplant often experience increases in disease and death. One approach, supportive and palliative care (SPC), focuses on relieving symptoms of stress from serious illness and care through physical, cultural, psychological, social, spiritual, and ethical aspects. While a second approach, clinical management of comorbidities (CMC) focuses on managing multiple diseases, other than cancer, such as heart or lung diseases through physical exercise, strength training, stress reduction, medication management, dietary recommendations, and education. Giving SPC, CMC, or a combination of both may work better in improving quality of life and survival after a donor stem cell transplant compared to standard of care in patients with blood diseases.

Disease Sites: Hematologic

Phase: II/III

Investigator: Jayani, Reena

NCTID: NCT03870750

Protocol No: VICC-IDCTT23500

Learn More

Neuroblastoma Maintenance Therapy Trial

Multiple Cancer Types

Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter,
study for patients with neuroblastoma in remission. In this study subjects will receive 730
Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 250 mg/m2 BID (strata 1,
2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on
the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to
prevent recurrence.

Disease Sites: Endocrine, Neuroblastoma (Pediatrics), Neuroendocrine, Pediatrics

Phase: II

Investigator: Pastakia, Devang

NCTID: NCT02679144

Protocol No: VICCPED16157

Learn More

Improving Care after Inherited Cancer Testing (IMPACT) Study

Miscellaneous

This clinical trial investigates factors associated with access to genetic risk assessment, counseling, and testings services. The trial also seeks to refine and evaluate the effectiveness of online tools on improving cancer risk management practices and family communication of genetic test results.

Disease Sites: Miscellaneous

Phase: N/A

Investigator: Pal, Tuya

NCTID: NCT04763915

Protocol No: VICCSUPP2112

Learn More